Analysts Offer Insights on Healthcare Companies: Ultragenyx (NASDAQ: RARE) and Versartis (NASDAQ: VSAR)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx (NASDAQ: RARE) and Versartis (NASDAQ: VSAR) with bullish sentiments.

Ultragenyx (NASDAQ: RARE)

In a report released yesterday, Arlinda Lee from Canaccord Genuity assigned a Buy rating to Ultragenyx (NASDAQ: RARE), with a price target of $83. The company’s shares closed yesterday at $50.27, close to its 52-week low of $49.57.

According to TipRanks.com, Lee is a 1-star analyst with an average return of -0.8% and a 40.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Ultragenyx has an analyst consensus of Moderate Buy, with a price target consensus of $75.18.

Versartis (NASDAQ: VSAR)

In a report released yesterday, John Newman from Canaccord Genuity assigned a Buy rating to Versartis (NASDAQ: VSAR), with a price target of $28. The company’s shares closed yesterday at $18.35.

According to TipRanks.com, Newman is a 4-star analyst with an average return of 3.0% and a 42.1% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Versartis is Strong Buy and the average price target is $29.33, representing a 59.8% upside.

In a report issued on September 8, Piper Jaffray also reiterated a Buy rating on the stock with a $26 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.